In answer to a recent “Personal History” piece published on November 22, one respondent griped that it never would have been published but for the writer’s ...
Signs and symptoms of ocular surface disease could be significantly reduced within 4 days after treatment with shelf-stable ...
Lund, Sweden, 16 December 2025. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that GOOD-IDES-02, a global pivotal Phase 3 trial in anti-glomerular basement membrane (anti-GBM) ...
Three months after reporting a win in a phase 3 trial of its kidney transplant drug imlifidase—which is likely to pave the way for a first-time approval in the U.S.—Hansa Biopharma has stumbled in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback